Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery

Autor: Thomas Creasey, Nimish Shah, Jeremy Schofield, Kate Cwynarski, Matthew R. Wilson, Jeffery Smith, Toby A. Eyre, Cheuk Kie Cheung, Fiona Miall, Kim Linton, Katrina Parsons, Christopher P. Fox, Gavin Preston, Pamela McKay, Matthew J. Ahearne, Matthew A. Timmins, Almurtadha Mula Kh, Jahanzaib Khwaja, Nicolas Martinez-Calle, Johnathon Elliot

Publikováno v: Blood Adv
Wilson, M R, Eyre, T A, Martinez-Calle, N, Ahearne, M, Parsons, K E, Preston, G, Khwaja, J, Schofield, J, Elliot, J, Kh, A M, Shah, N, Cheung, C K, Timmins, M A, Creasey, T, Linton, K, Smith, J, Fox, C P, Miall, F, Cwynarski, K & McKay, P 2020, ' Timing of high-dose methotrexate CNS prophylaxis in DLBCL : An analysis of toxicity and impact on R-CHOP delivery ', Blood Advances, vol. 4, no. 15, pp. 3586-3593 . https://doi.org/10.1182/bloodadvances.2020002421

High-dose methotrexate (HD-MTX) is increasingly used as prophylaxis for patients with diffuse large B-cell lymphoma (DLBCL) at high risk of central nervous system (CNS) relapse. However, there is limited evidence to guide whether to intercalate HD-MT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6a2409dbd0bd720cf92cdf284785ac8
https://pubmed.ncbi.nlm.nih.gov/32761231